drugset

drugset / Trial / NCT06966401

Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

NCT06966401 ↗

Phase 3 Recruiting 850 enrolled Neurocrine Biosciences

NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate the long-term safety and tolerability of NBI-1065845 as an adjunctive treatment in participants with MDD.

Timeline

Start: 2025-04-16
Primary completion: 2029-05
Completion: 2030-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	OSAVAMPATOR	Small molecule	—	Oral

Indications